Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 9
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean beccaceci a (2 results)?
Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022.
Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini LE, D'Abramo A, Cicalini S, Lapa D, Pittalis S, Puro V, Rivano Capparuccia M, Giombini E, Gruber CEM, Garbuglia AR, Marani A, Vairo F, Girardi E, Vaia F, Nicastri E; INMI Monkeypox Group. Antinori A, et al. Euro Surveill. 2022 Jun;27(22):2200421. doi: 10.2807/1560-7917.ES.2022.27.22.2200421. Euro Surveill. 2022. PMID: 35656836 Free PMC article.
Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox.
Mazzotta V, Cozzi-Lepri A, Lanini S, Mondi A, Carletti F, Tavelli A, Gagliardini R, Vita S, Pinnetti C, Aguglia C, Colavita F, Faccendini P, Matusali G, Faraglia F, Beccacece A, Paulicelli J, Girardi E, Nicastri E, Vaia F, Maggi F, Antinori A. Mazzotta V, et al. Among authors: beccacece a. J Med Virol. 2023 Jun;95(6):e28868. doi: 10.1002/jmv.28868. J Med Virol. 2023. PMID: 37306318 Clinical Trial.
Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes.
Mondi A, Mastrorosa I, Piselli P, Cimaglia C, Matusali G, Carletti F, Giannico G, Milozzi E, Biliotti E, Di Bari S, Chinello P, Beccacece A, Faraglia F, Vittozzi P, Mosti S, Tetaj N, Stazi GV, Pinnetti C, Camici M, D'Annunzio A, Marani A, Fabeni L, Specchiarello E, Gruber CEM, Villanacci A, Minicucci S, Garbuglia AR, Ianniello S, Marchioni L, Taglietti F, D'Offizi G, Palmieri F, Nicastri E, Maggi F, Vaia F, Girardi E, Antinori A. Mondi A, et al. Among authors: beccacece a. J Med Virol. 2023 Jun;95(6):e28831. doi: 10.1002/jmv.28831. J Med Virol. 2023. PMID: 37246793
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Mastrorosa I, Gagliardini R, Segala FV, Mondi A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastri E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group. Mastrorosa I, et al. Among authors: beccacece a. EClinicalMedicine. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36936403 Free PMC article.
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Pasquini Z, Toschi A, Casadei B, Pellegrini C, D'Abramo A, Vita S, Beccacece A, Bussini L, Chionsini MC, Dentale N, Cantiani A, Lazzarotto T, Bartoletti M, Nicastri E, Zinzani P, Giannella M, Viale P. Pasquini Z, et al. Among authors: beccacece a. Hematol Oncol. 2023 Dec;41(5):904-911. doi: 10.1002/hon.3206. Epub 2023 Jul 15. Hematol Oncol. 2023. PMID: 37452579
Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination.
Matusali G, Petruccioli E, Cimini E, Colavita F, Bettini A, Tartaglia E, Sbarra S, Meschi S, Lapa D, Francalancia M, Bordi L, Mazzotta V, Coen S, Mizzoni K, Beccacece A, Nicastri E, Pierelli L, Antinori A, Girardi E, Vaia F, Sette A, Grifoni A, Goletti D, Puro V, Maggi F. Matusali G, et al. Among authors: beccacece a. Vaccines (Basel). 2023 Sep 28;11(10):1541. doi: 10.3390/vaccines11101541. Vaccines (Basel). 2023. PMID: 37896943 Free PMC article.
Tecovirimat concentrations and viral suppression in seminal fluid from patients with mpox.
Tempestilli M, Mondi A, Matusali G, Mariotti D, Pinnetti C, Beccacece A, Cimini E, Mazzotta V, Carletti F, Faccendini P, Maggi F, Girardi E, Nicastri E, Vaia F, Antinori A. Tempestilli M, et al. Among authors: beccacece a. Lancet Infect Dis. 2023 May;23(5):531-532. doi: 10.1016/S1473-3099(23)00214-1. Epub 2023 Mar 30. Lancet Infect Dis. 2023. PMID: 37004668 No abstract available.
Air pollution, SARS-CoV-2 incidence and COVID-19 mortality in Rome - a longitudinal study.
Nobile F, Michelozzi P, Ancona C, Cappai G, Cesaroni G, Davoli M, Di Martino M, Nicastri E, Girardi E, Beccacece A, Scognamiglio P, Sorge C, Vairo F, Stafoggia M. Nobile F, et al. Among authors: beccacece a. Eur Respir J. 2022 Jul 26;60(3):2200589. doi: 10.1183/13993003.00589-2022. Online ahead of print. Eur Respir J. 2022. PMID: 35896215 Free PMC article.
Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation.
Ciccosanti F, Antonioli M, Sacchi A, Notari S, Farina A, Beccacece A, Fusto M, Vergori A, D'Offizi G, Taglietti F, Antinori A, Nicastri E, Marchioni L, Palmieri F, Ippolito G, Piacentini M, Agrati C, Fimia GM. Ciccosanti F, et al. Among authors: beccacece a. Clin Proteomics. 2022 Nov 8;19(1):38. doi: 10.1186/s12014-022-09377-7. Clin Proteomics. 2022. PMID: 36348270 Free PMC article.
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A, Vita S, Maffongelli G, Beccacece A, Agrati C, Cimini E, Colavita F, Giancola ML, Cavasio A, Nicastri E; Spallanzani COVID-19 Case Investigation Team. D'Abramo A, et al. Among authors: beccacece a. Front Immunol. 2022 May 27;13:911339. doi: 10.3389/fimmu.2022.911339. eCollection 2022. Front Immunol. 2022. PMID: 35711444 Free PMC article.
22 results